PGE2 and angiogenesis.
The angiogenic capability of PGE2 was tested by implanting pellets of an ethylene vinyl acetate slow release polymer containing PGE2 on the chorioallantoic membrane of 8-day-old chicken embryos. Elvax pellets releasing approximately 0.2, 2.0, or 20 ng/day PGE2 were found to induce neovascular responses. In contrast, pellets releasing 2.0 or 20 ng/day of either PGA2, PGF2, or TXB2 did not appear to be angiogenic when compared with PGE2. These release rates of PGE2 are similar to those reported for a variety of tumors, activated macrophages, inflammatory exudates, and rheumatoid synovia, suggesting that PGE2 may be a key factor in various neovascular reactions.
D000481:Allantoin / Q000502:physiology*; D000818:Animals; D001808:Blood Vessels / Q000187:drug effects / Q000196:embryology*; D002642:Chick Embryo; D002823:Chorion / Q000187:drug effects / Q000502:physiology*; D015232:Dinoprostone; D011145:Polyvinyls / Q000494:pharmacology*; D011453:Prostaglandins / Q000494:pharmacology; D011458:Prostaglandins E / Q000494:pharmacology*; D013329:Structure-Activity Relationship
D011145:Polyvinyls; D011453:Prostaglandins; D011458:Prostaglandins E; C016438:ethylenevinylacetate copolymer; D000481:Allantoin; D015232:Dinoprostone